DexCom Inc.
DXCM | NASDAQ
$84.13
+$1.84 (+2.24%)
Nov 2, 2026, 10:18 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | 4.66B | 4.03B | 3.62B | 2.91B | 2.45B | 1.93B |
Cost of Revenue | 1.86B | 1.59B | 1.33B | 1.03B | 768M | 646.6M |
Gross Profit | 2.8B | 2.44B | 2.29B | 1.88B | 1.68B | 1.28B |
Operating Income | 911.8M | 600M | 597.7M | 391.2M | 265.8M | 299.5M |
Interest Income | 112.7M | 134.2M | 135M | 23.8M | 1.7M | 16.1M |
Pretax Income | 1.09B | 709M | 710.4M | 390.8M | 256.8M | 225M |
Net Income | 836.3M | 576.2M | 541.5M | 341.2M | 216.9M | 493.6M |
Selling & General & Admin | 1.29B | 1.29B | 1.19B | 1.01B | 810.5M | 620.7M |
Research & Development | 599.1M | 552.4M | 505.8M | 484.2M | 604.2M | 359.9M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 1.89B | 1.84B | 1.69B | 1.49B | 1.41B | 980.6M |
Interest Expense | 18.3M | 19M | 20.3M | 18.6M | 18.8M | 84.7M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 3.75B | 3.43B | 3.02B | 2.52B | 2.18B | 1.63B |
Income Tax Expense | 252.1M | 132.8M | 168.9M | 49.6M | 39.9M | -268.6M |
Shares Outstanding (Basic) | 390.2M | 404.63M | 386M | 389.4M | 386.9M | 377.6M |
Shares Outstanding (Diluted) | 405.5M | 412.7M | 425.5M | 427.5M | 428.8M | 390M |
EPS (Basic) | 2.14 | 1.46 | 1.44 | 0.88 | 0.56 | 1.31 |
EPS (Diluted) | 2.09 | 1.42 | 1.30 | 0.80 | 0.51 | 1.27 |
EBITDA | 1.36B | 945.7M | 916.7M | 565.3M | 377.6M | 376.8M |
EBIT | 1.11B | 728M | 730.7M | 409.4M | 275.6M | 309.7M |
Depreciation & Amortization | 251.8M | 217.7M | 186M | 155.9M | 102M | 67.1M |
Add to Watchlist
Select watchlists to add or remove DXCM